Sentences with phrase «as ipilimumab»

NICE has also published a series of documents relating to the use of new therapies such as ipilimumab and BRAF inhibitors for advanced melanoma, which are available from the NICE website.

The Food and Drug Administration has cleared four checkpoint inhibitors for adults: Yervoy, also known as ipilimumab; Keytruda, or pembrolizumab; Opdivo, or nivolumab, and Tecentriq, or atezolizumab.

The other major class of immunotherapies are known as anti-CTLA-4 treatments, such as ipilimumab (Yervoy), which target a different mechanism to unleash immune cells to fight tumors.

Checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab have had a dramatic impact on treatment of several tumor types, including melanoma, lung cancer, head and neck cancers and others.

Drugs such as ipilimumab, which is given to people with advanced melanoma, work by activating the immune system to help it fight cancer.

«Combined checkpoint inhibitor treatments, such as ipilimumab - nivolumab, have produced higher response rates, but they can have serious side effects.

Not exact matches

The trial involved an experimental checkpoint inhibitor from Bristol - Myers Squibb called ipilimumab (now marketed as Yervoy)-- whose aim was to release the molecular brakes on her own army of T cells.

My apology comes with a small caveat, which is that ipilimumab (or Yervoy, as it has been branded) was not approved for prostate cancer.

As a follow - up act, the FDA in September 2015 gave the green light to the first cancer therapy to combine nivolumab and ipilimumab to treat certain patients with metastatic melanoma.

Indeed, the authors point out that Ipilimumab might better effect recurrence - free survival than adjuvant interferon and should be considered as an option by oncologists in this field considering its activity across subgroups including those with high tumor burden.

Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time at the ESMO 2016 Congress in Copenhagen.

«Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma.»

The EORTC 18071 phase III trial evaluated ipilimumab as adjuvant therapy for patients with high risk stage III melanoma.

As reported in 2015, the study met its primary endpoint after a median follow up of 2.3 years, with ipilimumab significantly improving recurrence - free survival.2 The drug was subsequently approved by the US Food and Drug Administration as adjuvant therapy for stage III melanomAs reported in 2015, the study met its primary endpoint after a median follow up of 2.3 years, with ipilimumab significantly improving recurrence - free survival.2 The drug was subsequently approved by the US Food and Drug Administration as adjuvant therapy for stage III melanomas adjuvant therapy for stage III melanoma.

Our intention with this study was to assess Ipilimumab as an adjuvant treatment for patients with completely resected stage III melanoma at high risk of recurrence.

Ipilimumab, sold as Yervoy, is an immunotherapy drug consisting of a monoclonal antibody that targets a protein receptor, CTLA - 4.

Mathias Chamaillard at the University of Lille, France, and his colleagues discovered that the skin cancer drug ipilimumab isn't as effective at treating cancer in mice born without bacteria in their gut, compared with mice with normal bacteria.

Combination immunotherapy with nivolumab and ipilimumab as tested in the kidney cancer study described here is already FDA - approved for treatment of melanoma, and is being tested for other cancers.

For those aged 75 and over (118 patients), the average progression - free survival time for those on the combination treatment could not be calculated as the patients» disease had not progressed yet; it was 5.3 months for those on nivolumab alone and four months for those on ipilimumab alone.

With enthusiasm for cancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sooner.

Currently, lymphadenectomy is an eligibility requirement for cutting - edge adjuvant therapy trials such as Southwest Oncology Group (SWOG) 1404 (ClinicalTrials.gov identifier: NCT02506153), which randomizes stage III melanoma patients to an anti — programmed death 1 antibody or standard - of - care adjuvant therapy (high - dose interferon or high - dose ipilimumab).

And again, that is an immunologic drug, and it was approved on the basis of prolonged relapse - free survival — that is, prolonged time to return of the tumor compared with ipilimumab, which as I mentioned was the standard since 2015.

«The side effects were quite high with the combination, with about 30 % of patients discontinuing due to treatment - related adverse events, as compared to 5 % with nivolumab and 13 % for ipilimumab.»

As a single agent, ipilimumab is approved as a second - line treatment, as well as adjuvant therapy for patients with completely resected melanomAs a single agent, ipilimumab is approved as a second - line treatment, as well as adjuvant therapy for patients with completely resected melanomas a second - line treatment, as well as adjuvant therapy for patients with completely resected melanomas well as adjuvant therapy for patients with completely resected melanomas adjuvant therapy for patients with completely resected melanoma.

Dr. Fong is experienced in research and clinical studies with the dendritic cell immunotherapy vaccine sipuleucel - T (Provenge) as well as the anti-CTLA-4 checkpoint immunotherapy ipilimumab.

This anti-PD-1 antibody works in a complementary fashion to ipilimumab and can be combined with it for more powerful results, as has been recently shown by a clinical trial conducted by CRI Scientific Advisory Council associate director Jedd Wolchok.

To date, several thousand cancer patients have received ipilimumab treatment in clinical trials for a variety of cancers, either as a monotherapy or in combination with other drugs.